Paula Pimenta-De-Souza

Paula Pimenta-De-Souza

Auto-generated profile, based on publicly available information

Paula Pimenta-De-Souza

Faculty of Pharmacy, Federal University of Rio de Janeiro, Avenida Carlos Chagas Filho, Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2026 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
PPPaula Pimenta-De-Souza
Paula Pimenta-De-Souza
ASAlice Ramos Silva
Alice Ramos Silva
VSValcieny Souza Sandes
Valcieny Souza Sandes
PPPatrícia Portella
Patrícia Portella
TGThaís Gouvêa
Thaís Gouvêa
ELElisangela Costa Lima
Elisangela Costa Lima
The growing prevalence of multidrug-resistant Gram-negative bacilli poses major challenges to the management of severe paediatric infections. Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are newer β-lactam/β-lactamase inhibitor combinations with established efficacy in adults. To synthesize current evidence on the efficacy, effectiveness, and safety of CZA and C/T in hospitalized children with severe infections. We conducted a systematic review, meta-analysis, and evidence map (PROSPERO CRD420251025715). Searches were performed in PubMed, Scopus, CENTRAL, Epistemonikos, LILACS, SciELO, and Web of Science. Eligible designs included randomized controlled trials (RCTs), cohort studies, case series, and case reports evaluating CZA or C/T for complicated intra-abdominal infections, complicated urinary tract infections (cUTI), pneumonia, or bacteraemia in patients aged 0-18 y. The primary outcome was 30-d mortality; secondary outcomes were clinical and microbiological cure and adverse events. Nineteen studies (4 RCTs, 9 case series, 6 case reports) involving 472 patients were included. Sixteen studies evaluated CZA and three evaluated C/T. All RCTs were phase II, industry-sponsored, and excluded critically ill children and carbapenem-resistant infections. According to the updated RoB 2 assessment, two trials had overall low risk of bias, and two presented some concerns, mainly related to missing outcome data. No deaths occurred in RCTs, whereas observational studies reported 8% mortality. Clinical and microbiological cure exceeded 80% across study designs. Adverse events were generally infrequent; neonatal events clustered in case series, but evidence was insufficient for statistical comparison across age groups. Certainty of evidence ranged from moderate (cUTI with susceptible pathogens) to very low (pneumonia and resistant infections). CZA and C/T appear promising for paediatric cUTI and complicated intra-abdominal infections, but the evidence base remains narrow and largely dependent on small, industry-funded trials. Independent RCTs including critically ill children and resistant infections are urgently needed.

9 November 2025 in Journal of Hospital Pharmacy and Health Services
Verified
Journal Article
Open access
TGThaís Aguiar Gouvêa
Thaís Aguiar Gouvêa
PPPaula Pimenta-De-Souza
Paula Pimenta-De-Souza
ASAlice Ramos Silva
Alice Ramos Silva
FFFernando Fernandez-Llimos
Fernando Fernandez-Llimos
ELElisangela Costa Lima
Elisangela Costa Lima
Objetivo: Este protocolo descreve uma revisão sistemática com metanálise e construção de mapa de lacunas de evidência, com o objetivo de avaliar a eficácia, efetividade e segurança das combinações antibióticas ceftazidima-avibactam e ceftolozano-tazobactam em crianças e adolescentes hospitalizados com infecções causadas por microrganismos multirresistentes (MDRs). A população pediátrica é especialmente vulnerável devido à escassez de dados farmacológicos, uso off-label e crescente resistência antimicrobiana. Métodos: A revisão está registrada na plataforma PROSPERO (CRD420251025715) e seguirá as diretrizes da Cochrane Collaboration. Serão incluídos ensaios clínicos randomizados, estudos observacionais (coorte, caso-controle, série e relatos de caso), envolvendo crianças de 0 a 18 anos com infecções intra-abdominais complicadas, urinárias complicadas, pneumonia hospitalar (com ou sem ventilação mecânica) ou bacteremia. Os comparadores serão antibióticos intravenosos com indicações similares. A busca será realizada nas bases MEDLINE, Embase, CENTRAL, LILACS, Scopus, Web of Science, Epistemonikos e Scielo, sem restrição de idioma ou data. Dois revisores independentes conduzirão a seleção, extração e avaliação de viés com as ferramentas RoB 2, ROBINS-I, JBI. A qualidade dos estudos incluídos será realizada conforme o GRADE. A metanálise usará modelo de efeitos aleatórios. Heterogeneidade será avaliada por estatística I². Será também elaborado um mapa de lacunas de evidência. O gráfico será gerado no RStudio, cruzando intervenções com desfechos e codificando os tipos de estudo por cor e densidade de evidência. Resultados esperados: Espera-se identificar a quantidade, qualidade e distribuição das evidências disponíveis, além de destacar lacunas críticas no conhecimento para subsidiar decisões clínicas e orientar pesquisas futuras.

27 March 2024 in HSJ
Verified
Journal Article
Open access
PDF file
ASAlice Ramos Silva
Alice Ramos Silva
PPPaula Pimenta-De-Souza
Paula Pimenta-De-Souza
CNCarlos Roberto Pinheiro Neto
Carlos Roberto Pinheiro Neto
DGDaniel Gigliotti
Daniel Gigliotti
MCMichele Costa Caetano
Michele Costa Caetano
ELElisangela Costa Lima
Elisangela Costa Lima
Objective: To analyze and describe the pharmacokinetic aspects of vancomycin usage in a cohort of critically ill children and to construct a pharmacokinetic model for this population. Method: We conducted an observational study in a pediatric intensive care unit from September 2017 to March 2019. Children receiving vancomycin with at least one serum measurement were included. Variables with a p-value lower than 0.2 in univariate analysis, and biologically plausible for inducing nephrotoxicity and not correlated with other predictors, were incorporated into logistic regression. Additionally, pharmacokinetic modeling was performed using the PMETRICS® package for patients with creatinine clearance (CLCR) > 30 mL/min. Result: The study included 70 children, with an average vancomycin dose of 60 mg/kg/day. Only eleven children achieved vancomycin levels within the target range (15-20 mg/L). No significant differences in doses/mg/kg/day were observed among children above, within, or below the vancomycin target range. In the multivariate model, children above the recommended serum range had an odds ratio of 4.6 [95% CI 1.4 – 17.2] for nephrotoxicity. A pharmacokinetic model was proposed using data from 15 children, estimating PK parameters for CLCR and V as 0.94 L/h and 5.71 L, respectively. Conclusion: Nephrotoxicity was associated with vancomycin plasma concentrations equal to or exceeding 15 mg/L. The developed model enhanced understanding of the drug’s behavior within this population, potentially aiding clinical practice in dose calculations and estimation of the area under the curve – a recommended parameter for vancomycin monitoring.